Your home for biotech and planetary health insight and opinion.
Let's build rapport.
The paradox of biotech protectionism: Why walling off China biotech weakens America
A US ban on Chinese biotech and clinical trial collaborations would return global pharmaceutical leadership to European pharmas and investors, slow American patient access to new medicines, and accelerate the US dependency that protectionism claims to prevent.
*Keep me informed! By providing your email, you are opting in to receiving marketing communications from RA Capital Management and its affiliates. We will never share your email. You are also agreeing to our privacy policy and our terms and conditions, which can be found here.
about
RApport is an online communications hub for members of the biotech and planetary health communities to share their ideas, problems, and solutions. Founded and run by employees of RA Capital, RApport is a place to gather insight and opinions from across these industries.
We encourage you to share your thoughts with us on Twitter @RApport_Bio.